美罗培南在新生儿重症监护室严重感染中的应用

Application of Meropenem in Newborn Infants with Severe Infections in Neonatal Intensive Care Unit

目的探讨美罗培南在新生儿重症监护室(NICU)治疗新生儿严重感染的疗效。方法对72例新生儿严重感染患儿采用常规治疗无效时应用美罗培南静脉治疗,50-60mg／(kg·d),2次/d,静脉滴注。临床疗效评价分为痊愈、显效、进步和无效。痊愈和显效作为有效统计。结果痊愈54例,显效6例,进步3例,无效9例。总有效率为83．3％。无不良反应发生。结论美罗培南适合用于NICU的新生儿严重感染的治疗。

Objective To investigate the therapy effect of meropenem in newborn infants with severe infections in neonatal intensive care unit（NICU）. Methods Seventy - two neonates with severe infections in NICU were involved in this study. When the patients were no response to routine bacteriophage, they were treated by venous injection of meropenem with a dose of 50-60 mg/（kg·d）, twice a day. The evaluation of clinical effect was divided into four degrees： healing, remarkable effect, advancement and invalidation. The degree of healing and remarkable effect was appraised as effective. Results At the end of the course treated with meropenem, 54 newborns were healed, 6 eases had remarkable effect, 3 cases had advanced effect and 9 cases had no effect. The total effective rate of meropenem reached 88.3%. No side effect was observed. Canclusion Meropenem is suitable for treating newborn infants with severe infections in NICU.